STB
VRTX icon

S&T Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

S&T Bank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23K Buy
5
+1
+25% +$466 ﹤0.01% 359
2025
Q4 		$1.81K Hold
4
– – ﹤0.01% 351
2025
Q3 		$1.57K Buy
4
+1
+33% +$418 ﹤0.01% 421
2025
Q2 		$1.34K Hold
3
– – ﹤0.01% 415
2025
Q1 		$1.45K Buy
+3
New +$1.4K ﹤0.01% 334

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

S&T Bank's VRTX Position: Q1 2026 in Review

S&T Bank increased its Vertex Pharmaceuticals (VRTX) stake by 25% in Q1 2026, buying an estimated $466 and bringing the position to 5 shares worth $2.23K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

S&T Bank first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • S&T Bank held 5 shares of Vertex Pharmaceuticals worth $2.23K as of Q1 2026.
  • S&T Bank bought 1 Vertex Pharmaceuticals share in Q1 2026, an estimated $466.
  • Vertex Pharmaceuticals made up ﹤0.01% of S&T Bank's portfolio in Q1 2026, its #359 holding.
  • S&T Bank first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on S&T Bank's 13F filing for Q1 2026, filed 13 May 2026.